11 December 2020 (Friday) - ASH Update

Some interesting snippets from the American Society of Hematology.

 

Adding Venetoclax to Cladribine and Cytarabine Backbone Improves Response Rates, Outcomes in Older Patients With AML The combination led to high rates of durable remissions and measurable residual disease negativity in older patients with newly diagnosed acute myeloid leukemia, according to results presented at the virtual 2020 ASH Annual Meeting.

Pediatric-Inspired Pegaspargase Regimen Shows Promise for Treatment of ALL/LBL The regimen, which was developed to avoid overlapping toxicities, was associated with deep responses and promising long-term efficacy in adults with newly diagnosed acute lymphocytic leukemia and lymphocytic lymphoma.

Mogamulizumab Demonstrates Antitumor Activity in Adult T-Cell Leukemia/Lymphoma
Nearly two-thirds of patients responded to treatment with mogamulizumab as a single agent or as part of a treatment combination.